VERA

VERA

Vera Therapeutics Inc

Rev โ€”top 1%5Y
Hold

Vera Therapeutics develops treatments for immunological diseases, focusing on atacicept for IgAN and other autoimmune kidney conditions, and MAU868 for BK viremia infections. Its therapies aim to improve patient outcomes through innovative biologics.

โš•๏ธ Healthcare NASDAQ Listed 2021 $ USD
$1,000 invested 30 years ago โ†’$2,696today

Score Overview

1 Year
Scoreโ€”
Net Growth-34.14%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growth-10x
Net TrendNever
Net Income Consistencyโ€”
Rev Growthโ€”
Rev Trend20%
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth-10x
Net TrendNever
Net Income Consistency
Rev Growthโ€”
Rev Trend20%
Revenue Consistency

See the full market ranking โ†’

Vera Therapeutics Inc fundamental performance

Across Vera Therapeutics Inc's full reported history, from 2021 to 2025, revenue held from $ 0.00 to $ 0.00 and net income went from -$ 32M to -$ 299M. Revenue increased in 20% of the years measured; net income in 0%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 29.99โ€”
1 Year2025-08-12
$ 21.1441.86%
5 Years2021-08-12
$ 16.7678.94%
10 Years2013-07-22
$ 1.1825x
20 Years2006-08-11
$ 0.5851x
30 Years1996-08-12
$ 11.13169.57%
All Time2021-05-14
$ 11.50160.78%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 0.00-$ 401M$ 499M
2025$ 0.00-$ 299M$ 714M
2024$ 0.00-$ 152M$ 640M
2023$ 1M-$ 95M$ 160M
2022$ 0.00-$ 89M$ 114M
IPO2021$ 0.00-$ 32M$ 79M

Explore beyond VERA

You're looking at Vera Therapeutics Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies